Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer By Ogkologos - December 19, 2025 246 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an updated analysis of the EMBER-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers FDA Approves Relacorilant with nab-Paclitaxel for Platinum-Resistant Epithelial Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer MOST POPULAR Mothers Raise Girls Together After Discovering They Were Swapped At Birth September 25, 2021 Women in science: Cancer research pioneers – part 2 January 25, 2023 Happy 29th Birthday OncoLink! March 7, 2023 FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a... December 10, 2024 Load more HOT NEWS Savolitinib Plus Osimertinib Show a High Response in EGFR-mutated NSCLC Progressed... Favourable Response More Likely with Neoadjuvant Dual Immune Checkpoint Inhibitor Than... Coping With Cancer Recurrence: My Perspective As Both a Patient and... World Cancer Day 2023: where does the UK stand?
